<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39641495</PMID><DateCompleted><Year>2024</Year><Month>12</Month><Day>06</Day></DateCompleted><DateRevised><Year>2024</Year><Month>12</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1756-185X</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>12</Issue><PubDate><Year>2024</Year><Month>Dec</Month></PubDate></JournalIssue><Title>International journal of rheumatic diseases</Title><ISOAbbreviation>Int J Rheum Dis</ISOAbbreviation></Journal><ArticleTitle>Coexisting Tubulointerstitial Inflammation and Damage Is a Risk Factor for Chronic Kidney Disease in Patients With Lupus Nephritis.</ArticleTitle><Pagination><StartPage>e15444</StartPage><MedlinePgn>e15444</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/1756-185X.15444</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study aims to determine whether the concurrent presence of tubulointerstitial inflammation (TII) and tubulointerstitial damage (TID) predicts the progression of chronic kidney disease (CKD) in patients with lupus nephritis (LN).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Data from 175 LN patients, collected at the time of renal biopsy, were analyzed. Patients were stratified into two groups based on the presence or absence of coexisting TII/TID. Uni- and multivariable Cox proportional hazard regression models were utilized to identify independent risk factors for CKD in LN patients.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 175 patients, 110 (62.9%) exhibited coexisting TII/TID, whereas 65 (37.1%) did not. Patients with coexisting TII/TID tended to be older and presented with higher levels of ESR and 24-h proteinuria, as well as lower levels of eGFR and hemoglobin compared to those without coexisting TII/TID. Over a mean follow-up period of 89.9&#x2009;months, CKD and end-stage renal disease occurred more frequently in patients with coexisting TII/TID. Notably, the presence of coexisting TII/TID was associated with a higher risk of CKD progression, with adjusted hazard ratios of 2.667 (95% CI: 1.333, 5.335, p&#x2009;=&#x2009;0.006) for all LN patients, 3.265 (95% CI: 1.451, 7.345, p&#x2009;=&#x2009;0.004) for those with class III, IV, and V LN, and 3.045 (95% CI: 1.289, 7.195, p&#x2009;=&#x2009;0.011) for those with class III, IV, V LN, and eGFR &#x2265;&#x2009;30&#x2009;mL/min/1.73&#x2009;m<sup>2</sup>.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">LN patients with coexisting TII/TID are at a heightened risk of kidney function deterioration at LN onset and subsequent development of CKD over the long term.</AbstractText><CopyrightInformation>&#xa9; 2024 The Author(s). International Journal of Rheumatic Diseases published by Asia Pacific League of Associations for Rheumatology and John Wiley &amp; Sons Australia, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jeong</LastName><ForeName>Hyemin</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Internal Medicine, Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Sung-Eun</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Internal Medicine, Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Ji-Hyoun</ForeName><Initials>JH</Initials><Identifier Source="ORCID">0000-0003-1113-2001</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Internal Medicine, Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Ji Shin</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Pathology, Chonnam National University Medical School &amp; Hospital, Gwangju, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Yoo-Duk</ForeName><Initials>YD</Initials><AffiliationInfo><Affiliation>Department of Pathology, Chonnam National University Medical School &amp; Hospital, Gwangju, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Dong-Jin</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Internal Medicine, Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Shin-Seok</ForeName><Initials>SS</Initials><Identifier Source="ORCID">0000-0001-6810-7355</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Internal Medicine, Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>BCRI19034</GrantID><Agency>Biomedical Research Institute of Chonnam National University Hospital</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Rheum Dis</MedlineTA><NlmUniqueID>101474930</NlmUniqueID><ISSNLinking>1756-1841</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051436" MajorTopicYN="Y">Renal Insufficiency, Chronic</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="Y">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009395" MajorTopicYN="Y">Nephritis, Interstitial</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005919" MajorTopicYN="N">Glomerular Filtration Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001706" MajorTopicYN="N">Biopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">chronic kidney disease</Keyword><Keyword MajorTopicYN="N">lupus nephritis</Keyword><Keyword MajorTopicYN="N">outcome</Keyword><Keyword MajorTopicYN="N">tubulointerstitial nephritis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>11</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>12</Month><Day>6</Day><Hour>12</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>12</Month><Day>6</Day><Hour>12</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>12</Month><Day>6</Day><Hour>8</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39641495</ArticleId><ArticleId IdType="doi">10.1111/1756-185X.15444</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>C. C. Mok, D. Y. Yap, S. V. Navarra, et&#xa0;al., &#x201c;Overview of Lupus Nephritis Management Guidelines and Perspective From Asia,&#x201d; International Journal of Rheumatic Diseases 16, no. 6 (2013): 625&#x2013;636.</Citation></Reference><Reference><Citation>M. G. Tektonidou, A. Dasgupta, and M. M. Ward, &#x201c;Risk of End&#x2010;Stage Renal Disease in Patients With Lupus Nephritis, 1971&#x2013;2015: A Systematic Review and Bayesian Meta&#x2010;Analysis,&#x201d; Arthritis &amp; Rhematology 68, no. 6 (2016): 1432&#x2013;1441.</Citation></Reference><Reference><Citation>M. L. Hermansen, J. Lindhardsen, C. Torp&#x2010;Pedersen, M. Faurschou, and S. Jacobsen, &#x201c;The Risk of Cardiovascular Morbidity and Cardiovascular Mortality in Systemic Lupus Erythematosus and Lupus Nephritis: A Danish Nationwide Population&#x2010;Based Cohort Study,&#x201d; Rheumatology (Oxford, England) 56, no. 5 (2017): 709&#x2013;715.</Citation></Reference><Reference><Citation>O. E. Ayodele, I. G. Okpechi, and C. R. Swanepoel, &#x201c;Predictors of Poor Renal Outcome in Patients With Biopsy&#x2010;Proven Lupus Nephritis,&#x201d; Nephrology (Carlton, Vic.) 15, no. 4 (2010): 482&#x2013;490.</Citation></Reference><Reference><Citation>G. Contreras, V. Pardo, C. Cely, et&#xa0;al., &#x201c;Factors Associated With Poor Outcomes in Patients With Lupus Nephritis,&#x201d; Lupus 14, no. 11 (2005): 890&#x2013;895.</Citation></Reference><Reference><Citation>K. E. Sada and H. Makino, &#x201c;Usefulness of ISN/RPS Classification of Lupus Nephritis,&#x201d; Journal of Korean Medical Science 24, no. Suppl (2009): S7&#x2013;S10.</Citation></Reference><Reference><Citation>A. O. Alsuwaida, &#x201c;Interstitial Inflammation and Long&#x2010;Term Renal Outcomes in Lupus Nephritis,&#x201d; Lupus 22, no. 14 (2013): 1446&#x2013;1454.</Citation></Reference><Reference><Citation>C. Hsieh, A. Chang, D. Brandt, R. Guttikonda, T. O. Utset, and M. R. Clark, &#x201c;Predicting Outcomes of Lupus Nephritis With Tubulointerstitial Inflammation and Scarring,&#x201d; Arthritis Care &amp; Research (Hoboken) 63, no. 6 (2011): 865&#x2013;874.</Citation></Reference><Reference><Citation>A. Broder, W. B. Mowrey, H. N. Khan, et&#xa0;al., &#x201c;Tubulointerstitial Damage Predicts End Stage Renal Disease in Lupus Nephritis With Preserved to Moderately Impaired Renal Function: A Retrospective Cohort Study,&#x201d; Seminars in Arthritis and Rheumatism 47, no. 4 (2018): 545&#x2013;551.</Citation></Reference><Reference><Citation>S. J. Moon, S. K. Kwok, J. H. Ju, et&#xa0;al., &#x201c;Predictors of Chronic Kidney Disease in Korean Patients With Lupus Nephritis,&#x201d; Journal of Rheumatology 38, no. 12 (2011): 2588&#x2013;2597.</Citation></Reference><Reference><Citation>D. J. Park, J. H. Kang, J. W. Lee, et&#xa0;al., &#x201c;Risk Factors to Predict the Development of Chronic Kidney Disease in Patients With Lupus Nephritis,&#x201d; Lupus 26, no. 11 (2017): 1139&#x2013;1148.</Citation></Reference><Reference><Citation>M. R. Clark, K. Trotter, and A. Chang, &#x201c;The Pathogenesis and Therapeutic Implications of Tubulointerstitial Inflammation in Human Lupus Nephritis,&#x201d; Seminars in Nephrology 35, no. 5 (2015): 455&#x2013;464.</Citation></Reference><Reference><Citation>M. C. Hochberg, &#x201c;Updating the American College of Rheumatology Revised Criteria for the Classification of Systemic Lupus Erythematosus,&#x201d; Arthritis and Rheumatism 40, no. 9 (1997): 1725.</Citation></Reference><Reference><Citation>D. D. Gladman, D. Ibanez, and M. B. Urowitz, &#x201c;Systemic Lupus Erythematosus Disease Activity Index 2000,&#x201d; Journal of Rheumatology 29, no. 2 (2002): 288&#x2013;291.</Citation></Reference><Reference><Citation>J. J. Weening, V. D. D'Agati, M. M. Schwartz, et&#xa0;al., &#x201c;The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited,&#x201d; Kidney International 65, no. 2 (2004): 521&#x2013;530.</Citation></Reference><Reference><Citation>H. A. Austin, 3rd, L. R. Muenz, K. M. Joyce, et&#xa0;al., &#x201c;Prognostic Factors in Lupus Nephritis. Contribution of Renal Histologic Data,&#x201d; American Journal of Medicine 75, no. 3 (1983): 382&#x2013;391.</Citation></Reference><Reference><Citation>Renal Disease Subcommittee of the American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response C, &#x201c;The American College of Rheumatology Response Criteria for Proliferative and Membranous Renal Disease in Systemic Lupus Erythematosus Clinical Trials,&#x201d; Arthritis and Rheumatism 54, no. 2 (2006): 421&#x2013;432.</Citation></Reference><Reference><Citation>A. S. Levey, J. Coresh, E. Balk, et&#xa0;al., &#x201c;National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification,&#x201d; Annals of Internal Medicine 139, no. 2 (2003): 137&#x2013;147.</Citation></Reference><Reference><Citation>O. C. Kwon, Y. Park, J. S. Lee, et&#xa0;al., &#x201c;Non&#x2010;albumin Proteinuria as a Parameter of Tubulointerstitial Inflammation in Lupus Nephritis,&#x201d; Clinical Rheumatology 38, no. 1 (2019): 235&#x2013;241.</Citation></Reference><Reference><Citation>M. H. Park, V. D'Agati, G. B. Appel, and C. L. Pirani, &#x201c;Tubulointerstitial Disease in Lupus Nephritis: Relationship to Immune Deposits, Interstitial Inflammation, Glomerular Changes, Renal Function, and Prognosis,&#x201d; Nephron 44, no. 4 (1986): 309&#x2013;319.</Citation></Reference><Reference><Citation>G. S. Hill, M. Delahousse, D. Nochy, et&#xa0;al., &#x201c;A New Morphologic Index for the Evaluation of Renal Biopsies in Lupus Nephritis,&#x201d; Kidney International 58, no. 3 (2000): 1160&#x2013;1173.</Citation></Reference><Reference><Citation>G. S. Hill, M. Delahousse, D. Nochy, et&#xa0;al., &#x201c;Predictive Power of the Second Renal Biopsy in Lupus Nephritis: Significance of Macrophages,&#x201d; Kidney International 59, no. 1 (2001): 304&#x2013;316.</Citation></Reference><Reference><Citation>J. M. Esdaile, C. Levinton, W. Federgreen, J. P. Hayslett, and M. Kashgarian, &#x201c;The Clinical and Renal Biopsy Predictors of Long&#x2010;Term Outcome in Lupus Nephritis: A Study of 87 Patients and Review of the Literature,&#x201d; Quarterly Journal of Medicine 72, no. 269 (1989): 779&#x2013;833.</Citation></Reference><Reference><Citation>O. C. Kwon, Y. M. Cho, J. S. Oh, et&#xa0;al., &#x201c;Factors Associated With Aggravation of Tubulointerstitial Damage on Repeated Biopsies in Lupus Nephritis Patients With Treatment Failure,&#x201d; Clinical and Experimental Rheumatology 38, no. 2 (2020): 239&#x2013;244.</Citation></Reference><Reference><Citation>J. R. O'Dell, R. C. Hays, S. J. Guggenheim, and J. C. Steigerwald, &#x201c;Tubulointerstitial Renal Disease in Systemic Lupus Erythematosus,&#x201d; Archives of Internal Medicine 145, no. 11 (1985): 1996&#x2013;1999.</Citation></Reference><Reference><Citation>C. Y. Wu, H. P. Chien, H. Y. Yang, et&#xa0;al., &#x201c;Role of Tubulointerstitial Lesions in Predicting Renal Outcome Among Pediatric Onset Lupus Nephritis &#x2010; A Retrospective Cohort Study,&#x201d; Journal of Microbiology, Immunology, and Infection 53, no. 1 (2020): 33&#x2013;41.</Citation></Reference><Reference><Citation>M. F. Gomes, C. Mardones, M. Xipell, et&#xa0;al., &#x201c;The Extent of Tubulointerstitial Inflammation Is an Independent Predictor of Renal Survival in Lupus Nephritis,&#x201d; Journal of Nephrology 34, no. 6 (2021): 1897&#x2013;1905.</Citation></Reference><Reference><Citation>K. S. Hodgkins and H. W. Schnaper, &#x201c;Tubulointerstitial Injury and the Progression of Chronic Kidney Disease,&#x201d; Pediatric Nephrology 27, no. 6 (2012): 901&#x2013;909.</Citation></Reference><Reference><Citation>E. J. ter Borg, P. E. de Jong, S. S. Meijer, and C. G. Kallenberg, &#x201c;Tubular Dysfunction in Proliferative Lupus Nephritis,&#x201d; American Journal of Nephrology 11, no. 1 (1991): 16&#x2013;22.</Citation></Reference><Reference><Citation>F. Yu, L. H. Wu, Y. Tan, et&#xa0;al., &#x201c;Tubulointerstitial Lesions of Patients With Lupus Nephritis Classified by the 2003 International Society of Nephrology and Renal Pathology Society System,&#x201d; Kidney International 77, no. 9 (2010): 820&#x2013;829.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>